Revision 1

#99991Store at -20C

1 Kit

(4 x 20 microliters)

Cell Signaling Technology

Orders: 877-616-CELL (2355) [email protected]

Support: 877-678-TECH (8324)

Web: [email protected] cellsignal.com

3 Trask LaneDanversMassachusetts01923USA
For Research Use Only. Not for Use in Diagnostic Procedures.
Product Includes Product # Quantity Mol. Wt Isotype/Source
MYST1 (D5T3R) Rabbit mAb 46862 20 µl 53 kDa Rabbit IgG
MYST2 (D4N3F) Rabbit mAb 58418 20 µl 80 kDa Rabbit IgG
MYST3 (E3P5T) Rabbit mAb 85460 20 µl 320 kDa Rabbit IgG
Anti-rabbit IgG, HRP-linked Antibody 7074 100 µl Goat 

Please visit cellsignal.com for individual component applications, species cross-reactivity, dilutions, protocols, and additional product information.

Description

The MYST Antibody Sampler Kit provides an economical means of detecting MYST family members using antibodies. The kit includes enough antibodies to perform two western blot experiments with each primary antibody.

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibodies.

Background

MYST1, also known as mammalian male absent on the first (MOF) and lysine acetyltransferase 8 (KAT8), is a member of the MYST (MOZ, YBF2, SAS2, and Tip60) family of histone acetyltransferases (1,2). As the catalytic subunit of two different histone acetyltransferase complexes, MSL and NSL, MYST1 is responsible for the majority of histone H4 lysine 16 acetylation in the cell. MYST1 also acetylates p53 on lysine 120 and is important for activation of pro-apoptotic genes (1,2). As a component of the MSL complex, MYST1 associates with MSL1, MSL2L1, and MSL3L1, and specifically acetylates histone H4 on lysine 16 (3-5). As part of the NSL complex, MYST1 associates with the MLL1 histone methyltransferase complex containing MLL1/KMT2A, ASH2L, HCFC1, WDR5, and RBBP5, and shows broader acetyltransferase activity for histone H4 on lysines 5, 8, and 16 (3-5). MYST1 plays a critical role in the regulation of transcription, DNA repair, autophagy, apoptosis, and emybryonic stem cell pluripotency and differentiation (1,2,6). Loss of MYST1 leads to a global reduction in histone H4 lysine 16 acetylation, a common hallmark found in many human cancers. A reduction of MYST1 protein levels and histone H4 lysine 16 acetylation is associated with poor prognosis in breast, renal, colorectal, gastric, and ovarian cancers (1).

MYST2, also known as HBO1 and lysine acetyltransferase 7 (KAT7), is the catalytic subunit of the HBO1 acetyltransferase complex, which consists of MYST2, MYST/ESA1-associated factor 6 (MEAF6), inhibitor of growth protein 4 (ING4) or inhibitor of growth protein 5 (ING5), and one of two families of scaffold proteins (JADE-1/2/3 or BRPF1/2/3) (7,8). The substrate specificity of the HBO1 complex is determined by the associated scaffold protein. HBO1 complexes containing JADE scaffold proteins acetylate histone H4 on lysines 5, 8, and 12, while complexes containing BRPF scaffold proteins acetylate histone H3 on lysines 14 and 23 (8). In addition, the scaffold protein appears to regulate the function of the HBO1 complex. Complexes containing JADE scaffold proteins bind to origin recognition complex 1 (ORC1) and regulate licensing of DNA replication, while HBO1 complexes containing BRPF scaffold proteins regulate transcription (8-11). MYST2 is required for regulation of cell proliferation (1), adipogenesis (12), embryonic development (13), and survival of fetal liver erythroblasts (14). In addition, MYST2 is overexpressed in several human cancers, including cancers of the testis, ovary, breast, stomach, esophagus, and bladder (15). The MYST2 gene is amplified and protein is overexpressed in breast cancers, and overexpression of MYST2 increases anchorage-independent growth of several breast cancer cell lines (16).

MYST3, also known as monocytic leukemia zinc finger protein (MOZ) and lysine acetyltransferase 6A (KAT6A), was first discovered as a fusion partner of CREBBP in acute myeloid leukemia. MYST3 contributes to Hox gene expression and segment identity during development (17-20). MYST3 forms an evolutionarily conserved complex with ING5, EAF6, and BRD1 and has been shown to be a coactivator for many different transcription factors, including PU.1, NRF2, and Runx family members (21-23). MYST3 is critical in hematopoietic stem cell maintenance, where it acts synergistically with polycomb member BMI1 (24). Inhibitors of MYST3 are being investigated for therapeutic value as they can induce senescence and decrease tumor growth (25).

  1. Yang, Y. et al. (2014) Front Med 8, 79-83.
  2. Li, X. and Dou, Y. (2010) Epigenetics 5, 185-8.
  3. Dou, Y. et al. (2005) Cell 121, 873-85.
  4. Li, X. et al. (2009) Mol Cell 36, 290-301.
  5. Cai, Y. et al. (2010) J Biol Chem 285, 4268-72.
  6. Füllgrabe, J. et al. (2013) Nature 500, 468-71.
  7. Avvakumov, N. et al. (2012) Mol Cell Biol 32, 689-703.
  8. Lalonde, M.E. et al. (2013) Genes Dev 27, 2009-24.
  9. Iizuka, M. and Stillman, B. (1999) J Biol Chem 274, 23027-34.
  10. Iizuka, M. et al. (2006) Mol Cell Biol 26, 1098-108.
  11. Miotto, B. and Struhl, K. (2010) Mol Cell 37, 57-66.
  12. Johmura, Y. et al. (2008) J Biol Chem 283, 2265-74.
  13. Kueh, A.J. et al. (2011) Mol Cell Biol 31, 845-60.
  14. Mishima, Y. et al. (2011) Blood 118, 2443-53.
  15. Iizuka, M. et al. (2009) Gene 436, 108-14.
  16. Hu, X. et al. (2009) Mol Cancer Res 7, 511-22.
  17. Borrow, J. et al. (1996) Nat Genet 14, 33-41.
  18. Champagne, N. et al. (2001) Oncogene 20, 404-9.
  19. Crump, J.G. et al. (2006) Development 133, 2661-9.
  20. Voss, A.K. et al. (2009) Dev Cell 17, 674-86.
  21. Katsumoto, T. et al. (2006) Genes Dev 20, 1321-30.
  22. Ohta, K. et al. (2007) Biochem J 402, 559-66.
  23. Bristow, C.A. and Shore, P. (2003) Nucleic Acids Res 31, 2735-44.
  24. Sheikh, B.N. et al. (2017) Exp Hematol 47, 83-97.e8.
  25. Baell, J.B. et al. (2018) Nature 560, 253-257.

Background References

    Trademarks and Patents

    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

    使用に関する制限

    法的な権限を与えられたCSTの担当者が署名した書面によって別途明示的に合意された場合を除き、 CST、その関連会社または代理店が提供する製品には以下の条件が適用されます。お客様が定める条件でここに定められた条件に含まれるものを超えるもの、 または、ここに定められた条件と異なるものは、法的な権限を与えられたCSTの担当者が別途書面にて受諾した場合を除き、拒絶され、 いかなる効力も効果も有しません。

    研究専用 (For Research Use Only) またはこれに類似する表示がされた製品は、 いかなる目的についても FDA または外国もしくは国内のその他の規制機関により承認、認可または許可を受けていません。 お客様は製品を診断もしくは治療目的で使用してはならず、また、製品に表示された内容に違反する方法で使用してはなりません。 CST が販売または使用許諾する製品は、エンドユーザーであるお客様に対し、使途を研究および開発のみに限定して提供されるものです。 診断、予防もしくは治療目的で製品を使用することまたは製品を再販売 (単独であるか他の製品等の一部であるかを問いません) もしくはその他の商業的利用の目的で購入することについては、CST から別途許諾を得る必要があります。 お客様は以下の事項を遵守しなければなりません。(a) CST の製品 (単独であるか他の資材と一緒であるかを問いません) を販売、使用許諾、貸与、寄付もしくはその他の態様で第三者に譲渡したり使用させたりしてはなりません。また、商用の製品を製造するために CST の製品を使用してはなりません。(b) 複製、改変、リバースエンジニアリング、逆コンパイル、 分解または他の方法により製品の構造または技術を解明しようとしてはなりません。また、 CST の製品またはサービスと競合する製品またはサービスを開発する目的で CST の製品を使用してはなりません。(c) CST の製品の商標、商号、ロゴ、特許または著作権に関する通知または表示を除去したり改変したりしてはなりません。(d) CST の製品をCST 製品販売条件(CST’s Product Terms of Sale) および該当する書面のみに従って使用しなければなりません。(e) CST の製品に関連してお客様が使用する第三者の製品またはサービスに関する使用許諾条件、 サービス提供条件またはこれに類する合意事項を遵守しなければなりません。